MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$24.5M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$21.8M |
| 3 |
Twist Bioscience
TWST
|
+$14M |
| 4 |
Janux Therapeutics
JANX
|
+$7.44M |
| 5 |
Aquestive Therapeutics
AQST
|
+$6.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$13.4M |
| 2 |
Morphic Holding, Inc. Common Stock
MORF
|
+$12.6M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$11M |
| 4 |
Xeris Biopharma Holdings
XERS
|
+$10.9M |
| 5 |
Axsome Therapeutics
AXSM
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$667M
| $128M | 19.21% |
7,648,268
| – | – |
2021 Q1
14 quarters
|
|
2
Insmed
INSM
$26.6B
| $44.9M | 6.74% |
615,391
| – | – |
2022 Q4
7 quarters
|
|
3
Olema Oncology, Inc. Common Stock
OLMA
$662M
| $32M | 4.8% |
2,680,596
+25,729
| +1% | +$329K |
2023 Q2
5 quarters
|
|
|
RNAM
4
DELISTED
Avidity Biosciences
RNAM
| $31.6M | 4.75% |
688,975
+563,975
| +451% | +$24.5M |
2024 Q2
1 quarter
|
|
5
DELISTED
Crinetics Pharmaceuticals
CRNX
| $26.9M | 4.03% |
525,845
-31,339
| -6% | -$1.62M |
2021 Q3
12 quarters
|
|
6
Edgewise Therapeutics
EWTX
$5.03B
| $24.5M | 3.67% |
917,166
+176,505
| +24% | +$3.51M |
2024 Q1
2 quarters
|
|
7
Iovance Biotherapeutics
IOVA
$3.59B
| $22.6M | 3.39% |
2,406,714
+40,000
| +2% | +$379K |
2022 Q2
9 quarters
|
|
8
Natera
NTRA
$46.3B
| $22.5M | 3.37% |
177,099
+2,288
| +1% | +$263K |
2024 Q1
2 quarters
|
|
|
9
Rocket Pharmaceuticals
RCKT
$257M
| $19.7M | 2.95% |
+1,066,373
| New | +$21.8M |
2024 Q3
0 quarters
|
|
10
Mirum Pharmaceuticals
MIRM
$6.14B
| $19.2M | 2.88% |
492,723
+154
| +0% | +$6.14K |
2024 Q2
1 quarter
|
|
11
Ultragenyx Pharmaceutical
RARE
$1.64B
| $18.3M | 2.75% |
329,733
-50,819
| -13% | -$2.59M |
2024 Q1
2 quarters
|
|
12
DELISTED
iTeos Therapeutics
ITOS
| $17.8M | 2.67% |
1,745,943
| – | – |
2020 Q3
16 quarters
|
|
13
MoonLake Immunotherapeutics
MLTX
$1.06B
| $17.6M | 2.64% |
349,063
+5,828
| +2% | +$273K |
2023 Q2
5 quarters
|
|
14
Lantheus
LNTH
$6.64B
| $16.5M | 2.47% |
150,182
+182
| +0.1% | +$18.9K |
2024 Q2
1 quarter
|
|
15
Madrigal Pharmaceuticals
MDGL
$9.9B
| $15.4M | 2.3% |
72,395
+1,210
| +2% | +$310K |
2022 Q2
9 quarters
|
|
16
Disc Medicine
IRON
$3.64B
| $15.3M | 2.3% |
311,761
+6,103
| +2% | +$287K |
2023 Q4
3 quarters
|
|
17
Relay Therapeutics
RLAY
$4B
| $14.4M | 2.16% |
2,033,041
+758,582
| +60% | +$5.67M |
2023 Q1
6 quarters
|
|
|
18
Twist Bioscience
TWST
$7.4B
| $13.3M | 2% |
+294,930
| New | +$14M |
2024 Q3
0 quarters
|
|
19
Revolution Medicines
RVMD
$37.3B
| $13.2M | 1.98% |
291,391
+1,995
| +0.7% | +$86.9K |
2021 Q3
12 quarters
|
|
20
Guardant Health
GH
$20.5B
| $11.5M | 1.72% |
499,170
-830
| -0.2% | -$23.5K |
2024 Q2
1 quarter
|
|
21
DELISTED
Akero Therapeutics
AKRO
| $11.3M | 1.69% |
392,544
+6,554
| +2% | +$171K |
2024 Q1
2 quarters
|
|
22
DELISTED
KalVista Pharmaceuticals
KALV
| $10.4M | 1.56% |
896,915
+14,978
| +2% | +$188K |
2024 Q1
2 quarters
|
|
23
Compass Therapeutics
CMPX
$139M
| $10.4M | 1.56% |
5,641,894
+636,808
| +13% | +$794K |
2024 Q1
2 quarters
|
|
24
Cartesian Therapeutics
RNAC
$194M
| $10.1M | 1.52% |
629,423
+369,727
| +142% | +$5.78M |
2024 Q2
1 quarter
|
|
25
Sutro Biopharma
STRO
$163M
| $9.8M | 1.47% |
283,206
-21,129
| -7% | -$828K |
2024 Q1
2 quarters
|
|
Similar funds
MPM BioImpact's Q3 2024 Portfolio in Review
As of Q3 2024, MPM BioImpact held 54 positions worth $667M, up 3.6% from $644M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
MPM BioImpact's Q3 2024 filing shows 10 new, 20 increased, 7 reduced and 11 closed positions. Its largest new stake was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M. The largest sale was Alkermes, an estimated $13.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- MPM BioImpact's largest Q3 2024 buy was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M.
- MPM BioImpact added most to Avidity Biosciences in Q3 2024, an estimated $24.5M increase.
- MPM BioImpact's biggest Q3 2024 reduction was 89bio, cutting an estimated $6.66M.
- MPM BioImpact fully exited Alkermes in Q3 2024, selling an estimated $13.4M.
- MPM BioImpact's ten largest holdings make up 56% of its $667M portfolio in Q3 2024.
- MPM BioImpact opened 10 new positions and closed 11 in Q3 2024.
- MPM BioImpact's portfolio value rose 3.6% quarter-over-quarter to $667M.
Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.